TAP off—tumors on
B Seliger, MJ Maeurer, S Ferrone - Immunology today, 1997 - cell.com
B Seliger, MJ Maeurer, S Ferrone
Immunology today, 1997•cell.comThe molecular characterization of T-cell-defined tumor-associated antigens has provided
targets for cell-mediated immunotherapy for malignant diseases. The success of this strategy
is negatively influenced by structural and functional abnormalities of major histocompatibility
complex (MHC) class I molecules, which provide tumor cells with resistance to T-cell-
mediated immune recognition. This article reviews the physiology of the MHC class I
processing machinery and describes the deficiencies of this pathway in malignant cells.
targets for cell-mediated immunotherapy for malignant diseases. The success of this strategy
is negatively influenced by structural and functional abnormalities of major histocompatibility
complex (MHC) class I molecules, which provide tumor cells with resistance to T-cell-
mediated immune recognition. This article reviews the physiology of the MHC class I
processing machinery and describes the deficiencies of this pathway in malignant cells.
Abstract
The molecular characterization of T-cell-defined tumor-associated antigens has provided targets for cell-mediated immunotherapy for malignant diseases. The success of this strategy is negatively influenced by structural and functional abnormalities of major histocompatibility complex (MHC) class I molecules, which provide tumor cells with resistance to T-cell-mediated immune recognition. This article reviews the physiology of the MHC class I processing machinery and describes the deficiencies of this pathway in malignant cells.
cell.com